Browsing by Subject "Parkinson's disease"
Now showing items 1-10 of 28
-
2-Aminopyrimidines as dual adenosine A1/A2A antagonists
(Elsevier, 2015)In this study thirteen 2-aminopyrimidine derivatives were synthesised and screened as potential antagonists of adenosine A1 and A2A receptors in order to further investigate the structure activity relationships of this ... -
5-Hydroxy-1-tetralone analogues as dual A1/A2A receptor antagonists for the potential treatment of neurological conditions
(North-West University, 2018)Parkinson's disease (PD), a classic movement disorder, is the second most common neurological condition after Alzheimer's disease, with higher incidence and prevalence in advanced age — consequently, PD patients' quality ... -
5-Hydroxy-1-tetralone analogues as dual A1/A2A receptor antagonists for the potential treatment of neurological conditions
(North-West University (South Africa), Potchefstroom Campus, 2018)Parkinson’s disease (PD), a classic movement disorder, is the second most common neurological condition after Alzheimer’s disease, with higher incidence and prevalence in advanced age — consequently, PD patients’ quality ... -
Adenosine A1/A2A receptor antagonistic properties of selected 2-substituted benzoxazinone and quinazolinone derivatives
(North-West University (South Africa), Potchefstroom Campus, 2018)The A1 and A2A adenosine receptor antagonists are the subject of extensive research based on their aptitude for ameliorating Parkinson’s disease related cognitive deficits (A1 adenosine receptor subtype) and motor dysfunction ... -
Advances in GBA-associated Parkinson's disease: pathology, presentation and therapies
(Elsevier, 2016)GBA mutations are to date the most common genetic risk factor for Parkinson's disease. The GBA gene encodes the lysomal hydrolase glucocerebrosidase. Whilst bi-allelic GBA mutations cause Gaucher disease, both mono- and ... -
Benzopyrone represents a privilege scaffold to identify novel adenosine A1/A2A receptor antagonists
(Elsevier, 2018)Adenosine receptor antagonists are under investigation as potential drug candidates for the treatment of certain cancers, neurological disorders, depression and potentially improve tumour immunotherapy. The benzo-γ-pyrone ... -
Benzyloxynitrostyrene analogues: a novel class of selective and highly potent inhibitors of monoamine oxidase B
(Elsevier, 2017)This study examines a series of novel 3-benzyloxy-β-nitrostyrene analogues as a novel class of inhibitors of the monoamine oxidase (MAO) enzymes. MAO inhibitors are considered useful for the treatment of depression and ... -
C2-substituted quinazolinone derivatives exhibit A1 and/or A2A adenosine receptor affinities in the low micromolar range
(Elsevier, 2020)Antagonists of the adenosine receptors (A1 and A2A subtypes) are widely researched as potential drug candidates for their role in Parkinson’s disease-related cognitive deficits (A1 subtype), motor dysfunction (A2A subtype) ... -
Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson’s disease
(Bentham Science, 2015)The current pharmacological therapies for the treatment of Parkinson’s disease are mostly inadequate and recent, improved therapeutic agents are required. Two important molecular targets for the design of anti-parkinsonian ... -
Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease
(Elsevier, 2015)Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has become an accepted treatment for motor symptoms in a subset of Parkinson's disease (PD) patients. The mechanisms why DBS is effective are incompletely ...